File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Plasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene
  • Basic View
  • Metadata View
  • XML View
TitlePlasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene
 
AuthorsCheung, BMY
Ong, KL
Tso, AWK
Leung, RYH
Cherny, SS
Sham, PC
Lam, TH
Lam, KSL
 
KeywordsPharmacy and pharmacology environmental studies
Toxicology and environmental safety
 
Issue Date2011
 
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
 
CitationThe 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
 
AbstractINTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6–20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5–17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.
 
DescriptionThis journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics
Posters
 
ISSN1742-7835
2013 Impact Factor: 2.294
2013 SCImago Journal Rankings: 0.739
 
DOIhttp://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
 
DC FieldValue
dc.contributor.authorCheung, BMY
 
dc.contributor.authorOng, KL
 
dc.contributor.authorTso, AWK
 
dc.contributor.authorLeung, RYH
 
dc.contributor.authorCherny, SS
 
dc.contributor.authorSham, PC
 
dc.contributor.authorLam, TH
 
dc.contributor.authorLam, KSL
 
dc.date.accessioned2011-08-26T14:33:02Z
 
dc.date.available2011-08-26T14:33:02Z
 
dc.date.issued2011
 
dc.description.abstractINTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6–20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5–17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionThis journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics
 
dc.descriptionPosters
 
dc.description.otherThe 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146
 
dc.identifier.citationThe 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
 
dc.identifier.doihttp://dx.doi.org/10.1111/j.1742-7843.2011.00722.x
 
dc.identifier.epage103
 
dc.identifier.hkuros189576
 
dc.identifier.issn1742-7835
2013 Impact Factor: 2.294
2013 SCImago Journal Rankings: 0.739
 
dc.identifier.issuesuppl. s1
 
dc.identifier.spage102
 
dc.identifier.urihttp://hdl.handle.net/10722/137759
 
dc.identifier.volume109
 
dc.languageeng
 
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofBasic & Clinical Pharmacology & Toxicology
 
dc.rightsThe definitive version is available at www.blackwell-synergy.com
 
dc.subjectPharmacy and pharmacology environmental studies
 
dc.subjectToxicology and environmental safety
 
dc.titlePlasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Cheung, BMY</contributor.author>
<contributor.author>Ong, KL</contributor.author>
<contributor.author>Tso, AWK</contributor.author>
<contributor.author>Leung, RYH</contributor.author>
<contributor.author>Cherny, SS</contributor.author>
<contributor.author>Sham, PC</contributor.author>
<contributor.author>Lam, TH</contributor.author>
<contributor.author>Lam, KSL</contributor.author>
<date.accessioned>2011-08-26T14:33:02Z</date.accessioned>
<date.available>2011-08-26T14:33:02Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic &amp; Clinical Pharmacology &amp; Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146</identifier.citation>
<identifier.issn>1742-7835</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/137759</identifier.uri>
<description>This journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics</description>
<description>Posters</description>
<description.abstract>INTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6&#8211;20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5&#8211;17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.</description.abstract>
<language>eng</language>
<publisher>Blackwell Publishing Ltd. The Journal&apos;s web site is located at http://www.blackwellpublishing.com/journals/PTO</publisher>
<relation.ispartof>Basic &amp; Clinical Pharmacology &amp; Toxicology</relation.ispartof>
<rights>The definitive version is available at www.blackwell-synergy.com</rights>
<subject>Pharmacy and pharmacology environmental studies</subject>
<subject>Toxicology and environmental safety</subject>
<title>Plasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene</title>
<type>Conference_Paper</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1111/j.1742-7843.2011.00722.x</identifier.doi>
<identifier.hkuros>189576</identifier.hkuros>
<identifier.volume>109</identifier.volume>
<identifier.issue>suppl. s1</identifier.issue>
<identifier.spage>102</identifier.spage>
<identifier.epage>103</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
<description.other>The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic &amp; Clinical Pharmacology &amp; Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/137759/1/re01.htm</bitstream.url>
</item>